Pharma BD Deal Intelligence

Novartis AG / Relation Therapeutics Limited

2025 · Co-Development · $1.8B · Complete

Relation Therapeutics and Novartis entered a multi-program strategic collaboration to discover and validate novel targets for atopic diseases using Relation's AI and human-tissue data platform paired with Novartis's immuno-dermatology expertise. Relation receives USD 55 million in combined upfront payment, equity investment and R&D funding, and is eligible for up to USD 1.70 billion in milestones plus tiered royalties. Relation leads observational studies generating functional cell atlases from patient tissue; Novartis holds worldwide development and commercialization rights to resulting programs.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Novartis AG deals